Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 88

Results For "EMA"

3789 News Found

Artemis Medicare to manage 650-bed VIMHANS Hospital in Rs. 520 South Delhi expansion
Hospitals | February 23, 2026

Artemis Medicare to manage 650-bed VIMHANS Hospital in Rs. 520 South Delhi expansion

The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore


FDA nod to AstraZeneca’s all-oral, fixed-duration therapy for CLL & SLL
Drug Approval | February 23, 2026

FDA nod to AstraZeneca’s all-oral, fixed-duration therapy for CLL & SLL

The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years


Surya Brasil eyes India expansion after 30% US growth
News | February 23, 2026

Surya Brasil eyes India expansion after 30% US growth

The new lineup features everything from the Color Fixation and Hair Therapy ranges to the Balanced Cleansing Shampoo and Nourishment & Protection Conditioner


BioVersys’ novel TB drug shows promising results in Phase 2a Trial
Clinical Trials | February 23, 2026

BioVersys’ novel TB drug shows promising results in Phase 2a Trial

The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project


Bavarian Nordic bags $22.5M Canadian vaccine order
News | February 23, 2026

Bavarian Nordic bags $22.5M Canadian vaccine order

The order will cover the manufacturing of bulk vaccine in 2026


Siegfried delivers strong 2025 performance, bolsters US expansion
News | February 23, 2026

Siegfried delivers strong 2025 performance, bolsters US expansion

Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates


Merck restructures Human Health division for future growth
News | February 23, 2026

Merck restructures Human Health division for future growth

Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential


FDA accepts Teva’s NDA for long-acting schizophrenia injection
Drug Approval | February 21, 2026

FDA accepts Teva’s NDA for long-acting schizophrenia injection

If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations


Zeus Hygia and Patch House Labs join forces to take nutraceuticals beyond the pill
News | February 21, 2026

Zeus Hygia and Patch House Labs join forces to take nutraceuticals beyond the pill

The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats